

# Differentiation of pluripotent stem cells to muscle fiber to model Duchenne muscular dystrophy


Jérôme Chal, Masayuki Oginuma, Ziad Al Tanoury, Bénédicte Gobert, Olga Sumara, Aurore Hick, Fanny Bousson, Yasmine Zidouni, Caroline Mursch, Philippe Moncuquet, Olivier Tassy, Stéphane Vincent, Ayako Miyanari, Agata Bera, Jean-Marie Garnier, Getzabel Guevara, Marie Hestin, Leif Kennedy, Shinichiro Hayashi, Bernadette Drayton, Thomas Cherrier, Barbara Gayraud-Morel, Emanuela Gussoni, Frédéric Relaix, Shahragim Tajbakhsh & Olivier Pourquie

Katherine Duncan & Diana Lin


PHGY 488

# Duchenne Muscular Dystrophy (DMD)

- Degenerative disease of the muscle
- X-linked recessive
- Dystrophin-deficient muscle cells
- Dystrophin: major structural protein in skeletal muscle
- Model: mdx mice



Dystrophin protein is a major structural protein in skeletal muscle




# Goal of the study

Develop a protocol for ES cells to differentiate into Pax7+ cells in order to generate muscle fibers in dystrophin-deficient cells, with the goal of restoring dystrophin in conditions such as Duchenne muscular dystrophy

→ Generation of striated, contractile fibers from mouse and human pluripotent cells

# Figure 1: Anterior-posterior maturation gradient








Figure 2: Wnt activation and BMP inhibition lead to a PSM fate



*Rspo3*: Wnt activator  
LDN193189: BMP inhibitor


M+ → *Msgn1*-repV+ cells  
P+ → *Pax3*-GFP+ cells  
Myog-repV+ cells

CDL: contains Chir, control  
(activates Wnt pathway)  
RDL: contains *Rspo3*

**PSM** → Presomitic Mesoderm

**Pax3** → Early and essential myogenic inducer expressed in the anterior PSM and in myogenic precursors

Figure 2: Wnt activation and BMP inhibition lead to a PSM fate




Lateral  
plate  
marker

Cardiac  
marker

Paraxial  
mesoderm  
markers


Pax3-GFP ES reporter line



Paraxial  
mesoderm  
markers

Neural  
marker

Figure 2: Wnt activation and BMP inhibition lead to a PSM fate



P+ cells positive for anterior PSM/somitic markers Pax3, Tbx18, Uncx, and Meox2







Figure 2: Wnt activation and BMP inhibition lead to a PSM fate



Green: genes specific for pPSM

Blue: genes specific for aPSM

Figure 3: Differentiation of multinucleated striated muscle fibers and associated Pax7+ cells from mouse ES cells *in vitro*






Figure 3: Differentiation of multinucleated striated muscle fibers and associated Pax7+ cells from mouse ES cells *in vitro*



k: highly organized striation      l, m: Pax7 cells show satellite-like activity

Differentiated fibers exhibited spontaneous *in vitro* contractions, indicating that the sarcomeric organization of the fibers was functional



Fetal muscle fiber marker


Myosin fast heavy chain

E11.5 trunk muscles: contain primary myofibers  
E17.5 back muscles: ongoing secondary myogenesis


## Figure 4: Pax7<sup>+</sup> cells grafted in dystrophin-deficient environment

Adult mdx muscle

1 month post-engraftment



Rag1<sup>-/-</sup> Dmd<sup>mdx-5Cv</sup> (mdx) mice →  
immunodeficient mice lacking dystrophin





Pax7<sup>+</sup> satellite cell-like cells located under the  
basal lamina of GFP<sup>+</sup> fibers

Pax7-GFP construct shown in green




Figure 5: mdx ES cells show an abnormal branching phenotype



More branching in mdx fibers in vitro vs. WT

Figure 6: Myogenic differentiation of human iPS cells




MF20: antibody for myosin heavy chain

## Discussion

- *In vitro* differentiation of mouse and human pluripotent cells into striated, linear, millimeter-long muscle fibers
- Strong BMP inhibition critical to prevent BMP4 expression → lateral plate formation
- Provides a tractable *in vitro* model to study the cell biology of DMD

## Caveats - study

- *In vitro* cultures were only similar to *in vivo*: PSM-like, satellite cell-like
  - Cultures could behave differently in *in vivo* environment
- Does not address the issue of engraftment failure in human trials
- A lot of unnecessary data to get a simple point across
- When making comparisons, often data not shown



## Caveats - paper

- Did not go into enough detail about related studies (more context needed)
- Difficult to understand figures
- Mechanisms were not thoroughly explained (required further research to understand)
- Authors assumed we had more background knowledge than we actually had



## Future endeavours

- Figure out how to successfully engraft cells into humans
- Clinical trials: attempt to rescue DMD in humans by injecting human iPSC derived Pax7<sup>+</sup> cells into human patients with DMD



Questions?